CN111004257B - Method for preparing RET inhibitor Selpercatinib - Google Patents
Method for preparing RET inhibitor Selpercatinib Download PDFInfo
- Publication number
- CN111004257B CN111004257B CN201911348328.1A CN201911348328A CN111004257B CN 111004257 B CN111004257 B CN 111004257B CN 201911348328 A CN201911348328 A CN 201911348328A CN 111004257 B CN111004257 B CN 111004257B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound represented
- compound
- reaction
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 229940121610 selpercatinib Drugs 0.000 title claims abstract description 31
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 title claims abstract description 19
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 title claims abstract description 19
- 239000003112 inhibitor Substances 0.000 title claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 44
- 150000001875 compounds Chemical class 0.000 claims description 96
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48
- 239000007787 solid Substances 0.000 claims description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 19
- 229910004373 HOAc Inorganic materials 0.000 claims description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 19
- 229910020889 NaBH3 Inorganic materials 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 10
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 9
- 239000012074 organic phase Substances 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000004537 pulping Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- 238000005658 halogenation reaction Methods 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229940126214 compound 3 Drugs 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 8
- 101150077555 Ret gene Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 5
- -1 Selpercatinib Compound Chemical class 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 4
- 206010071987 RET gene mutation Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- IDXKJSSOUXWLDB-UHFFFAOYSA-N 2-[4-(4-ethoxy-6-oxo-1h-pyridin-3-yl)-2-fluorophenyl]-n-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]acetamide Chemical compound CCOC1=CC(=O)NC=C1C(C=C1F)=CC=C1CC(=O)NC1=NOC(C(C)(C)C(F)(F)F)=C1 IDXKJSSOUXWLDB-UHFFFAOYSA-N 0.000 description 1
- KOLQINCWMXQEOF-UHFFFAOYSA-N 2-[6-(6,7-dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide Chemical compound COC=1C=C2C=C(C=NC2=CC=1OC)C1=CC=C(C=N1)CC(=O)NC1=CC(=NO1)C(C(F)(F)F)(C)C KOLQINCWMXQEOF-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GBLBJPZSROAGMF-RWYJCYHVSA-N CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 Chemical compound CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 GBLBJPZSROAGMF-RWYJCYHVSA-N 0.000 description 1
- 206010010539 Congenital megacolon Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a method for preparing RET inhibitor Selpercatinib. The preparation method has the advantages of milder halogenation reaction conditions, simpler reaction operation steps and post-treatment, fewer reaction steps, greatly improved total yield of the reaction and product purity of more than 99.0%.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a method for preparing a RET inhibitor Selpercatinib.
Background
RET is a protooncogene (The transfected REarranged gene). RET receptor tyrosine kinase is an oncogene that appears in various cancers including non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), etc., abnormal activation of which is a key driver leading to growth and proliferation of various solid tumors, and it has been found that various diseases occur in close relation to RET gene mutation, such as NSCLC, MTC, multiple endocrine adenomatosis type 2 (multiple endocrine neoplasma ii, MEN2), Papillary Thyroid Cancer (PTC), megacolon congenital, lung adenocarcinoma, etc.
RET gene variation includes gene fusion and activating point mutations, which can lead to excessive activation of the RET signaling pathway and uncontrolled cell growth. RET gene fusions occur in 2% of non-small cell lung cancers (NSCLC), 10-20% of thyroid cancers and a few other cancer types. Whereas activating RET point mutations occur in 60% of patients with Medullary Thyroid Carcinoma (MTC). Cancers carrying the variation of the RET gene are largely dependent on abnormal activation of this protein kinase to promote their proliferation and growth, and thus these cancers are very sensitive to RET inhibitors.
At present, selective and specific medicines and therapies aiming at RET are not approved by regulatory agencies such as FDA, and no selective RET inhibitor is on the market all over the world. A total of 17 selective RET inhibitor drugs are currently under investigation, with 2 in phase 2, 3 in phase 1, 6 in Discovery stage, and 6 reported without progression. The selective Ret inhibitor drugs associated with tumor indications entered 3 out of 3 in the clinic, with stage 2 clinic 1 (selpercatinib/LOXO-292), and stage 1 clinic 2 (pralseatinib/BLU-667, BOS-172738). Another 2 drugs, BOS-589 (phase 2 clinical), GSK-3179106 (phase 1 clinical), are used in intestinal diseases such as irritable bowel syndrome, gastrointestinal pain, inflammatory bowel disease.
Selpercatinib is a highly specific, potent oral RET inhibitor obtained when LOXO Oncology is purchased from gifts. It can inhibit not only the natural RET signaling pathway but also the acquired resistance mechanisms that may occur. It has been identified by FDA-granted breakthrough therapy to treat NSCLC patients carrying RET gene fusions and MTC patients carrying RET activating mutations, as well as patients with advanced thyroid cancer carrying RET gene fusions. From the current clinical test, the treatment effect is very good and more accurate, and the biochemical index remission rate obtains a good result. In addition, the compound is effective not only for patients with RET gene mutation, but also for patients with RET gene fusion. Finally, of particular interest is the very low side effects. The structural formula of the high-selectivity RET gene mutation inhibitor Selpercatinib is a compound shown as a formula I:
the current method for preparing the RET inhibitor Selpercatinib still needs to be improved.
Disclosure of Invention
The present invention is directed to solving, at least to some extent, one of the technical problems in the related art. Therefore, the invention aims to provide a method for preparing the RET inhibitor Selpercatinib, which has the advantages of few synthesis steps, mild reaction conditions, high reaction yield in each step, simplicity and convenience in operation, high total yield of reaction products and high purity of the obtained products.
In one aspect of the invention, the invention provides a method for preparing a compound RET inhibitor Selpercatinib shown in formula I. According to an embodiment of the invention, the method comprises:
(1) contacting a compound represented by formula 1 with a compound represented by formula 2 to obtain a compound represented by formula 3;
(2) contacting a compound of formula 3 with a compound of formula 4 to obtain a compound of formula I,
the inventor finds that the method adopts the existing easily-obtained drug intermediate (compound 1) and obtains the target compound Selpercatinib after halogenation reaction and reductive amination, the halogenation reaction condition is milder, the reaction operation steps and the post-treatment are simpler and more convenient, the reaction steps are fewer, the total yield of the reaction is greatly improved, and the product purity reaches more than 99.0%.
The term "contacting" as used herein is to be understood broadly and can be any means that enables a chemical reaction of at least two reactants, such as mixing the two reactants under appropriate conditions. The reactants to be contacted may be mixed with stirring as necessary, and thus, the type of stirring is not particularly limited, and may be, for example, mechanical stirring, that is, stirring under the action of a mechanical force.
Herein, a "compound of formula N" is also sometimes referred to herein as "compound N", where N is any integer from 1 to 4, e.g., "compound of formula 2" may also be referred to herein as "compound 2".
The terms "first", "second" and "first" are used herein for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.
According to an embodiment of the present invention, the above method for preparing the compound represented by formula 3, the compound represented by formula I, may further have at least one of the following additional technical features:
the chemical reactions described herein may be performed according to any method known in the art, according to embodiments of the present invention. The source of the raw materials for preparing the compound represented by formula 3, the compound represented by formula I is not particularly limited, and it may be prepared by any known method or may be commercially available.
According to an embodiment of the present invention, in step (1), the compound represented by formula 1, the compound represented by formula 2, K2CO3、Bu4The contact manner of NBr is not particularly limited. Preferably, the solvent of the reaction is selected from acetone. Thus, the compound represented by the formula 1, the compound represented by the formula 2, and K can be promoted2CO3、Bu4The NBr contact efficiency accelerates the reaction speed, and further improves the efficiency of preparing the compound shown in the formula 3 by using the method.
According to an embodiment of the present invention, in the step (1), the following steps are included: adding compound 1, compound 2 and K into acetone2CO3And Bu4NBr was stirred and heated to reflux. Filtering the reaction solution, concentrating the filtrate, pulping and purifying the obtained solid by using ethyl acetate, filtering the solid, and drying to obtain the compound shown in the formula 3. Thus, the efficiency of preparing the compound represented by formula 3 using this method can be further improved.
According to an embodiment of the present invention, in step (1), the compound represented by formula 1, the compound represented by formula 2, K2CO3、Bu4The molar ratio of NBr is 1 (1.0-1.3): (1.1-1.4): 0.005-0.015), preferably 1,2, K2CO3、Bu4The molar ratio of NBr was 1:1.2:1.2: 0.01. Therefore, the utilization rate of the reactants is high, the waste of raw materials and reality is avoided, and the yield of the target compound is high.
According to an embodiment of the present invention, in the step (1), the compound represented by formula 1, the compound represented by formula 2, and K may be reacted at 60 ℃2CO3、Bu4NBr contact reaction is carried out for 11-14 hours, and the preferable reaction time is 12 hours.
According to a specific embodiment of the present invention, in the step (1), the following steps are included: to acetone (300mL) was added Compound 1(33.2g, 0.1mol), Compound 2(18.4g, 0.12mol), and K2CO3(16.6g, 0.12mol) and tetrabutylammonium bromide (Bu4NBr) (3.2g, 0.01mol), heated with stirring, and reacted at 60 ℃ under reflux for 12 h. Filtering the reaction solution, concentrating the filtrate, pulping the obtained solid with ethyl acetate (120mL), purifying, filtering the solid, and drying to obtain the compound shown in the formula 3.
According to an embodiment of the present invention, in the step (2), the compound represented by formula 3, the compound represented by formula 4, HOAc, NaBH3The contact manner of CN is not particularly limited. Preferably, the solvent of the reaction is selected from CH2ClCH2A mixed solvent of Cl and MeOH. Thus, the compound represented by the formula 3, the compound represented by the formula 4, HOAc, NaBH can be promoted3CN contact efficiency, reaction speed is accelerated, and the efficiency of preparing the compound shown in the formula I by using the method is further improved.
According to an embodiment of the present invention, in the step (2), the following steps are included: mixing compound 3, compound 4, HOAc and NaBH3CN addition of CH2ClCH2Cl and MeOH, the mixture was stirred and the reaction was stirred. After the reaction solution was cooled to room temperature, saturated NaHCO was added3After the solution was adjusted to pH 10, DCM and MeOH were added and extracted. Drying the organic phase by using anhydrous sodium sulfate, concentrating under reduced pressure, pulping and purifying the obtained solid by using ethyl acetate, filtering the solid, and drying to obtain the compound Selpercatinib shown in the formula I. Therefore, the efficiency of preparing the compound shown in the formula I by using the method can be further improved.
According to an embodiment of the invention, in step (2), compound 3, compound 4, HOAc, NaBH3The molar ratio of CN is 1 (1.0-1.4) to 1.1-1.5 (1.2-1.5), preferably 3, 4, HOAc, NaBH3The molar ratio of CN is 1:1.2: 1.3. therefore, the utilization rate of reactants is high, the waste of raw materials and reality can not be caused, and the yield and the purity of the target compound are high.
According to an embodiment of the present invention, in step (2), compound 3, compound 4, HOAc, NaBH3CN and CH2ClCH2And stirring and heating the mixture of Cl and MeOH to 70-85 ℃, stirring and reacting for 3-7 h, preferably stirring and heating the mixture to 80 ℃, and stirring and reacting for 4 h. ByThe compound 3, the compound 4, HOAc, NaBH can be improved3CN is contacted, so that the efficiency of preparing the compound shown in the formula I by using the method is further improved.
According to a specific embodiment of the present invention, in the step (2), the following steps are included: compound 3(40.5g, 0.1mol), compound 4(16.5g, 0.12mol), HOAc (7.8g, 0.13mol), NaBH3CN (40.5g, 0.13mol) was added to CH2ClCH2Cl (400mL) and MeOH (250mL), stirred and warmed to 80 deg.C and the reaction stirred for 4 h. After the reaction solution was cooled to room temperature, saturated NaHCO was added3The solution was then adjusted to pH 10 and extracted by addition of DCM (400mL) and MeOH (40 mL). The organic phase is dried by anhydrous sodium sulfate and then concentrated under reduced pressure, the obtained solid is pulped and purified by ethyl acetate (400mL), and the solid is filtered and dried to obtain the compound Selpercatinib shown in the formula I.
According to the examples of the present invention, the synthetic route of the compound Selpercatinib of formula I can be as follows:
the preparation method of Selpercatinib reported in the prior art uses 1, 2-dimethyloxirane and hydroxyl in a compound 1 for alkylation, the reaction is a high-temperature and high-pressure tube sealing reaction, the danger is high, and the requirements on reaction equipment and operators are high during industrialization. The preparation method of Selpercatinib adopts the existing easily obtained drug intermediate (compound 1), and the target compound Selpercatinib is obtained after the halogenation reaction and the reduction ammoniation, the halogenation reaction condition is milder, the reaction operation steps and the post-treatment are simpler and more convenient, the reaction steps are fewer, the total yield of the reaction is greatly improved, and the product purity reaches more than 99.0 percent.
Detailed Description
The following describes embodiments of the present invention in detail. The following examples are illustrative only and are not to be construed as limiting the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
EXAMPLE 1 Synthesis of Compound represented by formula 3
To acetone (300mL) was added Compound 1(33.2g, 0.1mol), Compound 2(18.4g, 0.12mol), and K2CO3(16.6g, 0.12mol) and tetrabutylammonium bromide (3.2g, 0.01mol), heated with stirring and reacted at 60 ℃ under reflux for 12 h. The reaction solution was filtered, the filtrate was concentrated, and the obtained solid was purified by slurrying with ethyl acetate (120mL), and the solid was filtered and dried to obtain a compound represented by formula 3 in an amount of 32.6g with a yield of 80.7%.
LC-MS(APCI):m/z＝405.4(M+1)+。
EXAMPLE 2 Synthesis of Compound represented by formula 3
To acetone (300mL) was added Compound 1(33.2g, 0.1mol), Compound 2(15.3g, 0.1mol), and K2CO3(15.2g, 0.11mol) and Bu4NBr (1.6g, 0.005mol), heated with stirring, reacted at 60 ℃ under reflux for 11 h. The reaction solution was filtered, the filtrate was concentrated, and the obtained solid was purified by slurrying with ethyl acetate (120mL), and the solid was filtered and dried to obtain the compound represented by formula 3 in an amount of 31.2g with a yield of 77.1%.
EXAMPLE 3 Synthesis of Compound represented by formula 3
To acetone (300mL) was added Compound 1(33.2g, 0.1mol), Compound 2(19.9g, 0.13mol), and K2CO3(19.3g, 0.14mol) and Bu4NBr (4.8g, 0.015mol), heated with stirring, was reacted at 60 ℃ under reflux for 14 h. The reaction solution was filtered, the filtrate was concentrated, and the obtained solid was purified by slurrying with ethyl acetate (120mL), and the solid was filtered and dried to obtain a compound represented by formula 3 in an amount of 30.4g with a yield of 75.2%.
Example 4 Synthesis of Selpercatinib Compound of formula I
Compound 3(40.5g, 0.1mol), compound 4(16.5g, 0.12mol), HOAc (7.8g, 0.13mol), NaBH3CN (40.5g, 0.13mol) was added to CH2ClCH2Cl (400mL) and MeOH (250mL), stirred and warmed to 80 deg.C and the reaction stirred for 4 h. After the reaction solution was cooled to room temperature,adding saturated NaHCO3The solution was then adjusted to pH 10 and extracted by addition of DCM (400mL) and MeOH (40 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, the resulting solid was purified by slurrying with ethyl acetate (400mL), the solid was filtered and dried to give the compound Selpercatinib of formula I in an amount of 41.4g, yield 78.8% and HPLC purity 99.5%.
LC-MS(APCI):m/z＝526.4(M+1)+。
Example 5 Synthesis of Selpercatinib Compound of formula I
Compound 3(40.5g, 0.1mol), compound 4(13.7g, 0.1mol), HOAc (6.6g, 0.11mol), NaBH3CN (7.5g, 0.12mol) was added to CH2ClCH2Cl (400mL) and MeOH (250mL), stirred and warmed to 70 deg.C and the reaction stirred for 7 h. After the reaction solution was cooled to room temperature, saturated NaHCO was added3The solution was then adjusted to pH 10 and extracted by addition of DCM (400mL) and MeOH (40 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, the resulting solid was purified by slurrying with ethyl acetate (400mL), the solid was filtered and dried to give the compound Selpercatinib of formula I in an amount of 40.1g, yield 76.3% and HPLC purity 99.2%.
Example 6 Synthesis of Selpercatinib Compound of formula I
Compound 3(40.5g, 0.1mol), compound 4(19.2g, 0.14mol), HOAc (9.0g, 0.15mol), NaBH3CN (9.4g, 0.15mol) was added to CH2ClCH2Cl (400mL) and MeOH (250mL), stirred and warmed to 85 deg.C, and the reaction stirred for 3 h. After the reaction solution was cooled to room temperature, saturated NaHCO was added3The solution was then adjusted to pH 10 and extracted by addition of DCM (400mL) and MeOH (40 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the resulting solid was purified by slurrying with ethyl acetate (400mL), filtered and dried to give the compound Selpercatinib of formula I in an amount of 39.4g, a yield of 75.0% and an HPLC purity of 99.3%.
Example 7 Synthesis of Selpercatinib Compound of formula I
A mixture of compound 3(40.5g, 0.1mol), compound 4(13.0g, 0.095mol), HOAc (6.0g, 0.1mol), NaBH3CN (6.9g, 0.11mol) was added to CH2ClCH2Cl (400mL) and MeOH (250mL) stirredThe temperature is increased to 80 ℃, and the reaction is stirred for 4 hours. After the reaction solution was cooled to room temperature, saturated NaHCO was added3The solution was then adjusted to pH 10 and extracted by addition of DCM (400mL) and MeOH (40 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the resulting solid was purified by slurrying with ethyl acetate (400mL), filtered and dried to give the compound Selpercatinib of formula I in an amount of 23.6g, yield 44.9% and HPLC purity 97.8%.
Example 8 Synthesis of Selpercatinib Compound of formula I
Compound 3(40.5g, 0.1mol), compound 4(20.6g, 0.15mol), HOAc (10.8g, 0.18mol), NaBH3CN (11.3g, 0.18mol) was added to CH2ClCH2Cl (400mL) and MeOH (250mL), stirred and warmed to 80 deg.C and the reaction stirred for 4 h. After the reaction solution was cooled to room temperature, saturated NaHCO was added3The solution was then adjusted to pH 10 and extracted by addition of DCM (400mL) and MeOH (40 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the resulting solid was purified by slurrying with ethyl acetate (400mL), filtered and dried to give the compound Selpercatinib of formula I in an amount of 34.8g, a yield of 66.2% and an HPLC purity of 98.2%.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (10)
1. A method of preparing the RET inhibitor Selpercatinib, comprising:
(1) contacting a compound represented by formula 1 with a compound represented by formula 2 to obtain a compound represented by formula 3;
(2) contacting a compound of formula 3 with a compound of formula 4 to obtain a compound of formula I,
in the step (1), the method comprises the following steps: adding a compound represented by formula 1, a compound represented by formula 2, and K to acetone2CO3And Bu4NBr, stirring and heating, carrying out reflux reaction, filtering the reaction solution, concentrating the filtrate, pulping and purifying the obtained solid by using ethyl acetate, filtering the solid, and drying to obtain a compound shown in a formula 3;
in the step (2), the method comprises the following steps: mixing a compound shown as a formula 3, a compound shown as a formula 4, HOAc and NaBH3CN addition of CH2ClCH2Cl and MeOH, stirring and heating the mixture, stirring and reacting, cooling the reaction liquid to room temperature, and adding saturated NaHCO3Adjusting the pH value of the solution to 10, adding DCM and MeOH for extraction, drying an organic phase by using anhydrous sodium sulfate, concentrating under reduced pressure, pulping and purifying the obtained solid by using ethyl acetate, filtering the solid, and drying to obtain a compound Selpercatinib shown in the formula I.
2. The method according to claim 1, wherein in the step (1), the compound represented by formula 1, the compound represented by formula 2, K2CO3、Bu4The molar ratio of NBr is 1 (1.0-1.3) to 1.1-1.4 to 0.005-0.015.
3. The method according to claim 2, wherein in step (1), the compound represented by formula 1 is represented by formula (la)2, K2CO3、Bu4The molar ratio of NBr was 1:1.2:1.2: 0.01.
4. The method according to claim 1, wherein the compound represented by formula 1, the compound represented by formula 2, and K are reacted at 60 ℃ in step (1)2CO3、Bu4NBr contact reaction is carried out for 11-14 hours.
5. The method according to claim 4, wherein the compound represented by formula 1, the compound represented by formula 2, K are reacted at 60 ℃ in step (1)2CO3、Bu4The NBr contact reaction time was 12 hours.
6. The method according to claim 1, wherein in the step (2), the compound represented by formula 3, the compound represented by formula 4, HOAc, NaBH3The molar ratio of CN is 1 (1.0-1.4) to 1.1-1.5 to 1.2-1.5.
7. The method according to claim 6, wherein in the step (2), the compound represented by formula 3, the compound represented by formula 4, HOAc, NaBH3The molar ratio of CN is 1:1.2: 1.3.
8. the method according to claim 1, wherein in the step (2), the compound represented by formula 3, the compound represented by formula 4, HOAc, NaBH3CN and CH2ClCH2And stirring and heating the mixture of Cl and MeOH to 70-85 ℃, and stirring and reacting for 3-7 h.
9. The method according to claim 8, wherein in the step (2), the compound represented by formula 3, the compound represented by formula 4, HOAc, NaBH3CN and CH2ClCH2A mixture of Cl and MeOH was stirred and warmed to 80 deg.C and the reaction was stirred for 4 h.
10. The method of claim 1, wherein the first and second light sources are selected from the group consisting of,the method is characterized in that: in the step (1), the method comprises the following steps: to 300mL of acetone were added 33.2g of the compound represented by formula 1, 18.4g of the compound represented by formula 2, and 16.6g K2CO3And 3.2g of tetrabutylammonium bromide, stirring and heating, carrying out reflux reaction at 60 ℃ for 12 hours, filtering the reaction solution, concentrating the filtrate, pulping and purifying the obtained solid by using 120mL of ethyl acetate, filtering the solid, and drying to obtain a compound shown in the formula 3;
in the step (2), the method comprises the following steps: 40.5g of the compound represented by the formula 3, 16.5g of the compound represented by the formula 4, 7.8g of HOAc, and 40.5g of NaBH3CN addition of 400mL CH2ClCH2Cl and 250mL MeOH, stirring and heating to 80 ℃, stirring and reacting for 4h, cooling the reaction liquid to room temperature, and adding saturated NaHCO3Adjusting the pH value of the solution to 10, adding 400mL of DCM and 40mL of MeOH for extraction, drying an organic phase by using anhydrous sodium sulfate, concentrating under reduced pressure, pulping and purifying the obtained solid by using 400mL of ethyl acetate, filtering the solid, and drying to obtain a compound Selpercatinib shown in the formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911348328.1A CN111004257B (en) | 2019-12-24 | 2019-12-24 | Method for preparing RET inhibitor Selpercatinib |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911348328.1A CN111004257B (en) | 2019-12-24 | 2019-12-24 | Method for preparing RET inhibitor Selpercatinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111004257A CN111004257A (en) | 2020-04-14 |
| CN111004257B true CN111004257B (en) | 2021-06-29 |
Family
ID=70117695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911348328.1A Active CN111004257B (en) | 2019-12-24 | 2019-12-24 | Method for preparing RET inhibitor Selpercatinib |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111004257B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202202501A (en) * | 2020-04-17 | 2022-01-16 | 美商絡速藥業公司 | Crystalline ret inhibitor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019075092A1 (en) * | 2017-10-10 | 2019-04-18 | Charles Todd Eary | Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
| CN110156803A (en) * | 2017-02-27 | 2019-08-23 | 北京赛特明强医药科技有限公司 | Dioxanes and quinolines and the preparation method and application thereof |
| CN110382494A (en) * | 2016-10-10 | 2019-10-25 | 阿雷生物药品公司 | Pyrazolo [1,5-A] pyridine compounds being substituted are as RET kinase inhibitor |
-
2019
- 2019-12-24 CN CN201911348328.1A patent/CN111004257B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110382494A (en) * | 2016-10-10 | 2019-10-25 | 阿雷生物药品公司 | Pyrazolo [1,5-A] pyridine compounds being substituted are as RET kinase inhibitor |
| CN110156803A (en) * | 2017-02-27 | 2019-08-23 | 北京赛特明强医药科技有限公司 | Dioxanes and quinolines and the preparation method and application thereof |
| WO2019075092A1 (en) * | 2017-10-10 | 2019-04-18 | Charles Todd Eary | Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111004257A (en) | 2020-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neshat et al. | p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia | |
| CN111362923A (en) | Method for preparing RET inhibitor pracetib, intermediate of pracetib and preparation method of pracetib | |
| CN110938077B (en) | Method for synthesizing Avapritinib | |
| CN111440151A (en) | Method for preparing antitumor drug prasutinib | |
| CN111004257B (en) | Method for preparing RET inhibitor Selpercatinib | |
| CN111057075B (en) | RET inhibitor and preparation method thereof | |
| CN110724086A (en) | Synthetic method of pyrroltinib intermediate | |
| CN115461344B (en) | Crystal form A of GLP-1 receptor agonist and preparation method thereof | |
| CN112279838B (en) | Preparation method of pyrroltinib | |
| JPH10505354A (en) | Functional terpyridine-metal complexes, their preparation and oligonucleotide complexes with terpyridine-metal complexes | |
| CN113024517A (en) | Method for preparing erdastinib | |
| CN113024518A (en) | Preparation method of erdamitinib | |
| RU2712169C2 (en) | Novel polymorphic forms of icotinib phosphate and uses thereof | |
| CN102250138A (en) | Germatrane compound as well as preparation method and application thereof | |
| KR20170058093A (en) | New benzimidazole-ruthenium derivatives and pharmaceutical composition for preventing or treating cancer comprising the same | |
| CN111217821B (en) | Preparation method of series dioxane quinazoline derivatives | |
| CN114230568B (en) | Preparation method of HER2 small molecule inhibitor picatinib | |
| KR101804449B1 (en) | Polymorphic forms of icotinib and uses thereof | |
| CN114736205B (en) | Preparation method of compound Tomivosertib | |
| CN111072562B (en) | Tetrahydroisoquinoline derivative and preparation method and application thereof | |
| CN111978331B (en) | Preparation method of FLT3 and FGFR kinase inhibitor | |
| CN115819424B (en) | Indazole quinoxaline derivative, and synthetic method and application thereof | |
| CN115463131B (en) | Application of combination or complex of pyridine chalone or derivative and trans-platinum compound in preparation of medicines for treating cancers | |
| CN111057051A (en) | Novel synthesis method of PI3K inhibitor Alpelisib | |
| CN114213405A (en) | VEGFR inhibitor tivozanib preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for preparing RET inhibitor Selpercatinib Granted publication date: 20210629 Pledgee: Wuhan Optics Valley Small and Medium Duty Venture Capital Co.,Ltd. Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2024110000096 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |